ivosidenib
Selected indexed studies
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. (N Engl J Med, 2022) [PMID:35443108]
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. (Lancet Oncol, 2020) [PMID:32416072]
- Ivosidenib. (, 2006) [PMID:30222290]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. (2022) pubmed
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. (2020) pubmed
- Ivosidenib. (2006) pubmed
- Ivosidenib. (2012) pubmed
- Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. (2020) pubmed
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. (2023) pubmed
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. (2018) pubmed
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. (2021) pubmed
- Ivosidenib in acute myeloid leukemia. (2023) pubmed
- Ivosidenib: A Review in Advanced Cholangiocarcinoma. (2023) pubmed